Lori Garman1, Amanda J Vineyard2, Sherry R Crowe2, John B Harley3, Christina E Spooner4, Limone C Collins4, Michael R Nelson4, Renata J M Engler4, Judith A James5. 1. Oklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, OK 73104, USA; Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, OK 73104, USA. 2. Oklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, OK 73104, USA. 3. Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220, USA. 4. Walter Reed National Military Medical Center, Bethesda, MD 20814, USA. 5. Oklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, OK 73104, USA; Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, OK 73104, USA; Oklahoma University Health Science Center, Departments of Medicine and Pathology, Oklahoma City, OK 73104, USA. Electronic address: jamesj@omrf.org.
Abstract
BACKGROUND: Roughly half of U.S. adults do not receive recommended booster vaccinations, but protective antibody levels are rarely measured in adults. Demographic factors, vaccination history, and responses to other vaccinations could help identify at-risk individuals. We sought to characterize rates of seroconversion and determine associations of humoral responses to multiple vaccinations in healthy adults. METHODS: Humoral responses toward measles, mumps, tetanus toxoid, pertussis, hepatitis B surface antigen, and anthrax protective antigen were measured by ELISA in post-immunization samples from 1465 healthy U.S. military members. We examined the effects of demographic and clinical factors on immunization responses, as well as assessed correlations between vaccination responses. RESULTS: Subsets of boosted adults did not have seroprotective levels of antibodies toward measles (10.4%), mumps (9.4%), pertussis (4.7%), hepatitis B (8.6%) or protective antigen (14.4%) detected. Half-lives of antibody responses were generally long (>30 years). Measles and mumps antibody levels were correlated (r=0.31, p<0.001), but not associated with select demographic features or vaccination history. Measles and mumps antibody levels also correlated with tetanus antibody response (r=0.11, p<0.001). CONCLUSIONS: Vaccination responses are predominantly robust and vaccine specific. However, a small but significant portion of the vaccinated adult population may not have quantitative seroprotective antibody to common vaccine-preventable infections.
BACKGROUND: Roughly half of U.S. adults do not receive recommended booster vaccinations, but protective antibody levels are rarely measured in adults. Demographic factors, vaccination history, and responses to other vaccinations could help identify at-risk individuals. We sought to characterize rates of seroconversion and determine associations of humoral responses to multiple vaccinations in healthy adults. METHODS: Humoral responses toward measles, mumps, tetanus toxoid, pertussis, hepatitis B surface antigen, and anthrax protective antigen were measured by ELISA in post-immunization samples from 1465 healthy U.S. military members. We examined the effects of demographic and clinical factors on immunization responses, as well as assessed correlations between vaccination responses. RESULTS: Subsets of boosted adults did not have seroprotective levels of antibodies toward measles (10.4%), mumps (9.4%), pertussis (4.7%), hepatitis B (8.6%) or protective antigen (14.4%) detected. Half-lives of antibody responses were generally long (>30 years). Measles and mumps antibody levels were correlated (r=0.31, p<0.001), but not associated with select demographic features or vaccination history. Measles and mumps antibody levels also correlated with tetanus antibody response (r=0.11, p<0.001). CONCLUSIONS: Vaccination responses are predominantly robust and vaccine specific. However, a small but significant portion of the vaccinated adult population may not have quantitative seroprotective antibody to common vaccine-preventable infections.
Authors: Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland Journal: J Infect Dis Date: 2005-01-14 Impact factor: 5.226
Authors: C Christy; M E Pichichero; G F Reed; M D Decker; E L Anderson; M B Rennels; J A Englund; K M Edwards; M C Steinhoff Journal: Pediatrics Date: 1995-09 Impact factor: 7.124
Authors: David C Montefiori; Barbara Metch; M Juliana McElrath; Steve Self; Kent J Weinhold; Lawrence Corey Journal: J Infect Dis Date: 2004-10-28 Impact factor: 5.226
Authors: Eric K Dumas; Lori Garman; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Shyamal Choudhari; William D Picking; Judith A James; A Darise Farris Journal: Vaccine Date: 2017-05-11 Impact factor: 3.641
Authors: Erika Hammarlund; Archana Thomas; Elizabeth A Poore; Ian J Amanna; Abby E Rynko; Motomi Mori; Zunqiu Chen; Mark K Slifka Journal: Clin Infect Dis Date: 2016-03-21 Impact factor: 9.079
Authors: Eric K Dumas; Timothy Gross; Jason Larabee; Lance Pate; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Limone C Collins; Christina E Spooner; Hua Chen; Jimmy Ballard; Judith A James; A Darise Farris Journal: Clin Vaccine Immunol Date: 2017-11-06